logo
  

Stock Alert: Alector Down 18%

Shares of Alector Inc. (ALEC) are losing nearly 18% on Wednesday morning. ALEC is currently trading at $17.44, down $3.90 or 18.28%, on the Nasdaq.

In its preliminary data, Alector said its lead candidate AL001 in patients with frontotemporal dementia with a progranulin gene mutation was generally safe and well-tolerated in the Phase 1b study and after continuous dosing in 15 FTD-GRN patients in the Phase 2.

However, the company said that due to the COVID-19 pandemic, several clinical sites for the Phase 2 study were temporarily closed or conducted reduced or remote patient assessments during the evaluation period. As a result, some participants missed a dose of AL001 or missed clinical assessments during the treatment period. Alector is working closely with the sites, investigators and participants to manage future effects of the COVID-19 pandemic on the study.

In the mid-stage study, treatment with AL001 restored plasma progranulin levels in all subjects back to normal range while the majority of symptomatic FTD-GRN participants showed decreases in plasma neurofilament light chain levels from baseline.

A phase 3 study was initiated in July 2020, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,... CVS Health said it has installed time delay safe technology in all 392 Illinois CVS Pharmacy locations, including those in Target stores, to help reduce organized retail crime. The installation of new safes for controlled substances are anticipated to help prevent pharmacy robberies. There is also potential for associated diversion of controlled substance medications, including opioid medications.
RELATED NEWS
Follow RTT